Page last updated: 2024-11-02

pemoline and Lassitude

pemoline has been researched along with Lassitude in 26 studies

Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.

Research Excerpts

ExcerptRelevanceReference
"To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue."9.08Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."9.08The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
"Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients."6.67A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. ( Bass, B; Ebers, GC; Penman, M; Rice, GP; Weinshenker, BG, 1992)
"To compare the efficacy of 2 psychostimulant medications, methylphenidate hydrochloride (Ritalin) and pemoline (Cylert), with a placebo intervention for the treatment of fatigue in patients with HIV disease."5.09A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. ( Breitbart, W; Funesti-Esch, J; Kaim, M; Rosenfeld, B, 2001)
"To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue."5.08Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."5.08The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
" Search terms included multiple sclerosis, fatigue, medication treatments, amantadine, modafinil, aspirin, acetyl-l-carnitine, pemoline, 4-aminopyridine and randomized controlled trial (RCT)."4.95Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017)
" We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis."4.91Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015)
" Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis."4.86Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010)
" Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term."4.80Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000)
"Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients."2.67A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. ( Bass, B; Ebers, GC; Penman, M; Rice, GP; Weinshenker, BG, 1992)
"Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions."2.48Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012)
"Fatigue is recognized as one of the most disabling and common symptoms of MS."2.44Treating fatigue. ( Hum, S; Lapierre, Y, 2007)
"Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1."2.41Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001)
"Fatigue is a common symptom in patients with multiple sclerosis."2.40['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19908 (30.77)18.7374
1990's6 (23.08)18.2507
2000's7 (26.92)29.6817
2010's5 (19.23)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yang, TT1
Wang, L1
Deng, XY1
Yu, G1
Mücke, M1
Cuhls, H1
Peuckmann-Post, V1
Minton, O1
Stone, P1
Radbruch, L2
Ramsey, CS1
Werchan, PM1
Isdahl, WM1
Fischer, J1
Gibbons, JA1
Peuckmann, V1
Elsner, F1
Krumm, N1
Trottenberg, P1
Kirshbaum, M1
Induruwa, I1
Constantinescu, CS1
Gran, B1
LUCAS, CJ1
KNOWLES, JB1
Schwid, SR1
Murray, TJ1
Boërio, D1
Lefaucheur, JP1
Hogrel, JY1
Créange, A1
Lapierre, Y1
Hum, S1
Krupp, LB3
Coyle, PK2
Doscher, C2
Miller, A1
Cross, AH1
Jandorf, L1
Halper, J1
Johnson, B1
Morgante, L1
Grimson, R1
Geisler, MW1
Sliwinski, M1
Masur, DM1
Dulli, D1
Schutta, H1
Akerstedt, T1
Ficca, G1
Zimmermann, C1
Hohlfeld, R1
Brañas, P1
Jordan, R1
Fry-Smith, A1
Burls, A1
Hyde, C1
Breitbart, W1
Rosenfeld, B1
Kaim, M1
Funesti-Esch, J1
Christodoulou, C1
Valle-Jones, JC1
Weinshenker, BG1
Penman, M1
Bass, B1
Ebers, GC1
Rice, GP1
Meadley, RG1
Talland, GA1
McGuire, MT1
Orzack, MH1
Taylor, CL1
Kornetsky, C1
Chojnowski, JR1
Zydowicz, L1
Chojnowska-Jezierska, J1
Adamska-Dyniewska, H1
Strasser, H1
Müller-Limmroth, W1
Kagan, G1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093]40 participants (Anticipated)Observational2022-04-30Not yet recruiting
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]42 participants (Anticipated)Interventional2020-08-01Recruiting
Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020]100 participants (Anticipated)Interventional2015-12-31Recruiting
A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162]Early Phase 120 participants (Anticipated)Interventional2023-10-31Not yet recruiting
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525]Phase 359 participants (Actual)Interventional2010-06-30Completed
Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900]0 participants (Actual)Interventional2012-02-29Withdrawn (stopped due to Was unable to recruit subjects)
Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820]105 participants (Actual)Interventional2017-05-31Completed
Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate[NCT02643732]30 participants (Anticipated)Interventional2016-11-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

11 reviews available for pemoline and Lassitude

ArticleYear
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    Journal of the neurological sciences, 2017, Sep-15, Volume: 380

    Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig

2017
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2015, May-30, Issue:5

    Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea

2015
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11

    Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney

2010
Pharmacologic treatments for fatigue associated with palliative care.
    Clinical journal of oncology nursing, 2011, Volume: 15, Issue:4

    Topics: Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Evidence-Based Medicine; Fatigu

2011
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
[Pathophysiology and treatment of fatigue in multiple sclerosis].
    Revue neurologique, 2006, Volume: 162, Issue:3

    Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N

2006
Treating fatigue.
    International MS journal, 2007, Volume: 14, Issue:2

    Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents

2007
Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours.
    Chronobiology international, 1997, Volume: 14, Issue:2

    Topics: Amphetamine; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Fatigue; Humans; Mod

1997
['Fatigue' in multiple sclerosis].
    Der Nervenarzt, 1999, Volume: 70, Issue:6

    Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis;

1999
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
    Health technology assessment (Winchester, England), 2000, Volume: 4, Issue:27

    Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base

2000
Fatigue in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste

2001

Trials

10 trials available for pemoline and Lassitude

ArticleYear
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
    Archives of neurology, 1996, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C

1996
A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.
    Archives of internal medicine, 2001, Feb-12, Volume: 161, Issue:3

    Topics: Ambulatory Care; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; HIV Infect

2001
Pemoline in the treatment of psychogenic fatigue in general practice.
    The Practitioner, 1978, Volume: 221, Issue:1323

    Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Family Practice; Fatigue; Female; Humans; Pemo

1978
A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.
    Neurology, 1992, Volume: 42, Issue:8

    Topics: Adult; Double-Blind Method; Fatigue; Humans; Middle Aged; Multiple Sclerosis; Pemoline

1992
Tests of learning and memory with Cylert.
    Psychopharmacologia, 1967, Volume: 10, Issue:5

    Topics: Adult; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; Hydroxides; Lea

1967
A research report on the anti-fatigue effects of magnesium pemoline.
    Psychopharmacologia, 1968, Volume: 13, Issue:5

    Topics: Adult; Attention; Caffeine; Central Nervous System; Central Nervous System Stimulants; Fatigue; Fema

1968
[Effect of psychotropic drugs on the fatigue states based on psychological tests].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1970, Sep-15, Volume: 23, Issue:18

    Topics: Acetates; Adult; Caffeine; Central Nervous System Stimulants; Fatigue; Humans; Meclofenoxate; Pemoli

1970
[Physiological changes in the performance of older test persons during continuous tracking tasks following administration of a central nervous system stimulants].
    Arzneimittel-Forschung, 1973, Volume: 23, Issue:3

    Topics: Achievement; Adult; Aged; Arrhythmia, Sinus; Attention; Clinical Trials as Topic; Cybernetics; Fatig

1973
Clinical trial of pemoline in general practice.
    The British journal of clinical practice, 1974, Volume: 28, Issue:11

    Topics: Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Family Practice; Fatigue; Female; Humans

1974

Other Studies

5 other studies available for pemoline and Lassitude

ArticleYear
Acceleration tolerance at night with acute fatigue and stimulants.
    Aviation, space, and environmental medicine, 2008, Volume: 79, Issue:8

    Topics: Acceleration; Adaptation, Physiological; Adult; Aerospace Medicine; Amphetamine; Analysis of Varianc

2008
THE TRIAL OF A NEW STIMULANT, PEMOLINE, IN THE TREATMENT OF FATIGUE IN STUDENTS.
    Journal of the American College Health Association, 1963, Volume: 12

    Topics: Central Nervous System Agents; Central Nervous System Stimulants; Fatigue; Humans; Oxazoles; Pemolin

1963
Treating fatigue in patients with MS: one step forward, one step back.
    Neurology, 2005, Apr-12, Volume: 64, Issue:7

    Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants

2005
Fatigue in MS.
    Neurology, 1996, Volume: 47, Issue:5

    Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline

1996
A new anti-fatigue agent in general practice.
    The Practitioner, 1965, Volume: 195, Issue:169

    Topics: Adult; Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Middle Aged; Oxazoles

1965